0
0
March 7, 2026
MUMBAI — India is currently facing a silent crisis: non-communicable diseases (NCDs) now account for over 5.8 million deaths annually, representing a staggering 63% of all mortalities in the country. In response, a fundamental shift is occurring within the medical landscape, moving away from reactive “sick-care” toward proactive prevention. At the center of this transformation is Universal NutriScience (UNS), a leader in the “clinical pivot” that is elevating nutraceuticals from over-the-counter wellness products to evidence-based, doctor-prescribed therapies.
Backed by Kedaara Capital and drawing on the 30-year manufacturing legacy of Universal Medicare, UNS is challenging the traditional supplement market. By focusing on randomized clinical evidence and pharmaceutical-grade rigor, the company is addressing chronic conditions—ranging from infertility and hormonal imbalances to osteoarthritis—with the same precision usually reserved for prescription drugs.
From Retail Aisles to Doctor Consultations
The Indian nutraceutical market is projected to reach INR 113,000 crores by 2030. However, a significant gap remains in how these products are consumed. Currently, only 20–30% of sales in India occur under medical supervision, whereas in more developed markets, nearly 70–80% are retail-driven without professional guidance.
UNS aims to flip this script by positioning its portfolio within the “doctor-driven” segment. “There is clear medical acceptance brewing because consumers and providers alike are seeking evidence-backed solutions,” says Pratin Vete, CEO of Universal NutriScience. Vete, a veteran with over three decades of experience at pharma giants like Novartis and Emcure, views nutraceuticals as “preventive pillars” that complement, rather than compete with, traditional medicine.
The strategy involves the use of Novel Drug Delivery Systems (NDDS) and defined dosages to ensure that molecules like Coenzyme Q10 (CoQ10) or collagen peptides actually reach the intended tissues effectively.
Supporting the Journey to Parenthood
One of the most critical applications of this clinical approach is in reproductive health. Infertility now affects an estimated 15–20% of Indian couples—nearly 30 million people. Urbanization and delayed parenthood have exacerbated these numbers, leading many toward Assisted Reproductive Technologies (ART) like IVF.
UNS has dominated this space with specialized CoQ10 formulations. These are designed to combat oxidative stress, which can degrade oocyte (egg) quality in women and sperm motility in men.
“The future of nutrition is the right molecule for the right patient at the right stage of their disease,” notes Dr. Shailesh Ayyangar, Chairman of UNS and former head of GSK and Sanofi in India.
Recent meta-analyses support this targeted approach, showing that CoQ10 supplementation can improve clinical pregnancy rates in women with diminished ovarian reserve. However, experts remain cautious, noting that while clinical pregnancy rates may rise, data on live birth rates remains variable, necessitating continued research.
Bridging the Gap in Women’s Hormonal Health
Beyond fertility, the company is tackling Premenstrual Syndrome (PMS), a condition affecting 43% of Indian women of reproductive age. Despite its prevalence, only 27% are ever diagnosed, and fewer than 10% receive treatment.
UNS’s Primosa (Evening Primrose Oil) utilizes Gamma-Linolenic Acid (GLA) to stabilize hormonal fluctuations. Clinical trials indicate that GLA-rich formulations can significantly reduce PMS severity over a three-to-six-month period. To support this clinical push, the company’s Sakhi CSR initiative works in rural schools to reduce the stigma surrounding menstrual health, effectively acting as a bridge between education and diagnosis.
Orthopedics: Delaying the Scalpel
In the realm of aging and mobility, the focus has shifted to “preventive orthopedics.” As life expectancy rises, so does the incidence of osteoarthritis (OA). UNS’s collagen portfolio, including CollaFlex PRO+, targets cartilage health in the early stages of wear and tear.
A 2024 meta-analysis of 11 randomized controlled trials involving 870 participants confirmed that collagen supplementation significantly improved pain and physical function scores compared to placebos. For patients with mild-to-moderate OA, these interventions may potentially delay the need for invasive procedures like knee replacements.
The “Pharmaceuticalization” of Wellness
This trend is often described as the “pharmaceuticalization” of nutraceuticals—the blending of natural safety profiles with the clinical rigor of drug development.
Dr. Satya Dev Tiwari, an independent healthcare consultant, observes that this shift allows General Practitioners (GPs) to personalize prevention. “Nutraceuticals allow us to address root causes, such as micronutrient deficiencies or chronic inflammation, with a much lower risk profile than long-term synthetic drugs,” he explains.
However, the transition is not without hurdles. Independent reviews in journals such as Frontiers in Pharmacology warn of potential drug-nutraceutical interactions. For instance, certain supplements can inhibit enzymes like CYP3A4, affecting how the body processes other medications. This highlights why doctor supervision is vital.
Public Health Implications and Limitations
If successful, the UNS model could provide a blueprint for easing the burden on India’s overstretched healthcare system. By managing lifestyle-linked conditions through nutrition, the long-term costs associated with NCDs—which disproportionately affect women and the aging population—could be significantly reduced.
A Balanced Perspective: What Readers Should Know
While the data is promising, it is essential to view nutraceuticals with a balanced lens:
-
Not a “Cure-All”: Supplements are designed to support physiological function, not necessarily reverse advanced disease. Collagen helps manage symptoms but cannot “regrow” a completely eroded joint.
-
Placebo Effect: In studies involving PMS and general wellness, the placebo effect often plays a role, highlighting the need for larger, more robust Indian-specific trials.
-
Bioavailability: Not all supplements are created equal. The body’s ability to absorb these nutrients varies wildly based on the delivery system and individual metabolism.
-
Regulatory Gaps: India’s regulatory framework for nutraceuticals is still evolving. Consumers should be wary of “miracle claims” found in retail-only products that lack clinical backing.
Looking Ahead
With an ambitious goal of reaching INR 1,000 crores by FY28, Universal NutriScience plans to expand into urology and cardiology. For the average consumer, this “clinical pivot” means that the next time they reach for a supplement, it may not be from a social media recommendation, but rather a calculated part of a medical treatment plan.
By moving science out of the lab and into the daily lives of millions, India is beginning to treat “prevention” not just as a buzzword, but as a measurable medical outcome.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
ET HealthWorld (March 6, 2026). The Clinical Pivot: How Universal NutriScience Is Rewriting Preventive Healthcare in India. 2. PMC (2021). Prevalence of premenstrual syndrome and premenstrual dysphoric disorder among women in India. [DOI: 10.4103/jhp.jhp_1_21]
